Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

PURPOSE: Intergroup Rhabdomyosarcoma Study Group (IRSG) studies III and IV showed improved failure-free survival (FFS) rates with vincristine, dactinomycin, and cyclophosphamide (VAC; total cumulative cyclophosphamide dose, 26.4 g/m(2)) compared with vincristine and dactinomycin (VA) for patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Walterhouse, David O., Pappo, Alberto S., Meza, Jane L., Breneman, John C., Hayes-Jordan, Andrea A., Parham, David M., Cripe, Timothy P., Anderson, James R., Meyer, William H., Hawkins, Douglas S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209105/
https://ncbi.nlm.nih.gov/pubmed/25267746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.6787
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados